from existing rearrangements. We also identified three cell line models for investigating the pathology of, and therapeutic targets in, this apparently novel LMO2 subtype.
Stable and reproducible engraftment of primary adult and pediatric acute myeloid leukemia in NSG mice Leukemia (2011) Models of primary human acute myeloid leukemia (AML) are important tools to study various aspects of the pathophysiology of AML, like stem cell biology, multimodal drug therapies and development of resistance in vivo. In contrast to acute lymphoblastic leukemia, AML xenotransplant models are hampered by persistent problems of inadequate engraftment and a short-life span of the animals. Increasingly, immunodeficient strains evolved from the NOD/SCID strain to evade residual innate immunity (summarized in Shultz et al. 1 ). The NOD.Cg-Prkdc Scid IL2 rg tm1Wjll/ SzJ (NSG) mouse model is the product of a targeted deletion of the common gamma-chain and represents a substantial improvement leading to a complete and stable deficiency of mature lymphocytes and NK cells, a prolonged survival beyond 16 months of age and an acceptable radiation sensitivity highly permissive for engraftment of primary human cells. 2 Besides the animal strains, a variety of techniques are described to transplant human AML samples. Most of the previous studies published engraftment rates after intravenous infusion between 37.8 and 70% with a median delay from 8 weeks to 12 weeks. [3] [4] [5] The reported results are based on intramedullary injections to transplant human AML cells. We demonstrate a mean engraftment of 81.6% with a median delay of 10 weeks.
In this study, we used 6-to 10-week-old non-irradiated animals. 2 Â 10 6 unsorted fresh or frozen bone marrow (BM) and peripheral blood (PB) cells with a mean of 5.7 Â 10 5 hCD33 þ cells in a volume of 50 ml fetal calf serum were injected intrafemorally from 49 newly diagnosed adult and pediatric AML patients, 27 fresh samples (18 adult, 9 pediatric) and 22 frozen samples (20 adult, 2 pediatric). Engraftment rates reached 82%. Engraftment was monitored by weekly blood collections and FACS analysis for hCD45, complete blood counts and PCR of the a-satellite region of human chromosome 17. PCR amplifications were positive with less than 1 ng of human DNA in whole mouse blood after DNA extraction (Figure 1a) . Myeloid engraftment was confirmed with a FACS analysis of hCD33. Engrafted animals presented with hepatosplenomegaly, a significant anemia (8.7 g/dl haemoglobin (Hb) versus 11.0 g/dl Hb; P ¼ 0.002, two-sided Wilcoxon test) and thrombocytopenia (107 Â 10 3 /ml platelets versus 440 Â 10 3 /ml platelets; Po0.001, two-sided Wilcoxon test) (Figure 1b) as described by Ishikawa et al. 3 Engraftment of primary transplants was positive in 81.6% (40/49). All pediatric samples could be transplanted successfully (11/11) and adult samples engrafted in 76.3% (29/38). The overall median time to engraftment was 10 (3-23) weeks (adults 10 (5-23) weeks/pediatric 9 (3-19) weeks). Fresh samples engrafted in 96.3% of the cases with an overall median delay of 8 (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) weeks (adult 8 (5-20) weeks/pediatric 7 (3-16) weeks) whereas frozen samples showed a median time to engraftment of 19 (6-23) weeks (adult 17 (7-23) days/pediatric 19 (18-19) weeks) and were positive in 63.6%. Engraftment and time to engraftment was independent of the origin of the cells and the number of transplanted cells. Time to engraftment was significantly dependent on fresh or frozen samples used for transplantation (Po0.05) (Figure 1c ). Serial transplants with BM, liver and spleen as source from primary engrafted animals were successful in 63.9% with significantly shorter engraftment times. The hCD45 distribution in the PB varied from 2 to 76% and did not correlate with the hCD45 distribution in the liver, spleen and BM. In BM, the variation ranged from 2.3 to 97%, in the spleen from 0.8 to 59.5% and liver from 0 to 61% (Figure 2 ).
Thirty-six animals received sequential transplants with cells derived from primary grafts and demonstrated cytogenetic stability (data not shown). The molecular and cytogenetic characteristics of the transplanted AML samples are shown in Table 1 and in Supplementary Figure S1 (Supplementary Information and Supplementary Table 1 ). The level of Wilms' tumor gene expression was examined in 12 samples using quantitative RT-PCR to further specify engraftment of hCD45 þ /hCD33 þ as AML cells. In 8 of 12 samples (67%), a Wilms' tumor gene overexpression was observed 6 (see also Supplementary Information). In contrast to other observations, 5 neither the molecular nor the cytogenetic markers had an impact on the (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) weeks. Second grafts of adult samples showed a time to engraftment of 5 (2-6) weeks for fresh samples versus 10 (6-18) weeks for frozen samples. The differences were significant for adult fresh versus frozen for first (*P ¼ 0.025) and second transplants (*P ¼ 0.001). The reduced delay between first graft and second graft of fresh adult samples is also significant (*P ¼ 0.003). First grafts of pediatric samples showed a time to engraftment of 7 (3-16) weeks for fresh versus 19 weeks for frozen samples. Second grafts of pediatric samples showed a time to engraftment of 4 (2-6) weeks for fresh versus 14 (8-18) weeks for frozen samples. The difference was significant for adult fresh versus frozen for first transplants (*P ¼ 0.025).
success of engraftment because all pediatric samples and 83.3% of the adult samples engrafted successfully.
Successful serial transplants up to the fifth generation are currently performed with 2Â 10 6 unsorted cells with a mean of 1.5 Â 10 5 hCD33 þ cells in a volume of 50 ml FCS from fresh or frozen samples derived from the liver, spleen or BM. Overall, 63.9% engrafted successfully. The median delay of engraftment was reduced from 10 (3-23) weeks in the primary transplant to 9 (2-18) weeks in the secondary transplants. It seemed that engraftment delay diminishes with passage (preliminary data: mean delay for the third transplant: 4 weeks and for the fourth: 2 weeks). In secondary transplants, fresh samples engrafted in 75% with an overall median delay of 4 (2-6) weeks, whereas frozen samples had a median time to engraftment of 13 (6-19) weeks and were positive in 42.9% of the cases. Due to the single AML sample derived from PB, we were not able to compare the two different types of cells of origin. Sanchez et al. 5 reported successful serial transplantations with 2.5 Â 10 6 to 10 Â 10 6 unsorted hCD45 þ /hCD33 þ cells using sublethally irradiated NSG mice, which is consistent with engraftment of leukemia initiating cells (SL-IC). We can confirm these results in non-irradiated animals with substantially less hCD45 þ / hCD33 þ cells. In addition, besides BM and spleen, hCD45 þ / hCD33 þ cells derived from the liver of primary transplanted animals engrafted well. In our hands, serial transplants also showed a significantly reduced delay to engraftment and were not influenced by cells of origin or amount of injected cells. The repopulation capacity of these SL-IC seems to increase with the passages.
Furthermore Wunderlich et al. 7 recently reported an enhanced leukemic engraftment in a strain coined NSGS, that emerged from a cross breed between the NSG and NSS strain using sublethal TBI for conditioning. In addition to the NSG features NSS constitutively express human SCF, GM-SCF and IL-3 on a NOD/SCID background and marginally improved the engraftment of primary AML. 8 It is unclear whether this Letters to the Editor Table 1 Summary of cytogenetic and mutational analyses of selected AML samples The last rows indicate the samples used for serial transplantation and their disease latency. The numbers in both FLT3 columns indicates the ratio mutation to wild type.
constitutive cytokine stimulation induces a biased engraftment of a susceptible sub-population of human leukemic cells. We conclude that with more than 81% of engraftment, non-irradiated NSG mice are an excellent tool for xenotransplantation using unsorted primary AML samples from both children and adults. Serial transplantations with hCD45 þ cells of as low as 4 Â 10 3 cells using intrafemoral injection can be successfully applied and maintain cytogenetic stability from different sources with a reduced median time to engraftment. PCR amplification of the a-satellite region of human chromosome 17 proved to be simple and highly predictive for engraftment screening of human cells. The NSG model is a powerful tool for a variety of requirements like amplification of primary human AML samples, LS-IC assays and to assess individualized molecular treatment modalities in vivo on a large scale.
